ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2597

Degree of Initial Intracellular Folate Depletion May Predict Methotrexate Response in Juvenile Idiopathic Arthritis

Leon van Haandel1, Ryan S. Funk1, Maria F. Ibarra2, Mark F. Hoeltzel3, Andrew Lasky4, Daisy Dai5, Rodger Gaedigk1, J. Steven Leeder6 and Mara L Becker5, 1Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospital, Kansas City, MO, 2Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, 3Rheumatology Section, Children's Mercy Hospital, Kansas City, MO, 4Pediatrics Rheumatology, Children's Mercy Hospital, Kansas City, MO, 5Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO, 6Individualized medicine, Children's Mercy Hospital, Kansas City, MO

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers, clinical trials, methotrexate (MTX) and vitamins, Science

  • Tweet
  • Email
  • Print
Session Information

Session Title: Pediatric Rheumatology: Clinical and Therapeutic Disease IV: Childhood Therapeutics and Response

Session Type: Abstract Submissions (ACR)

Background/Purpose: Despite widespread use, there are no predictors of methotrexate (MTX) response or toxicity.  The objective of this study is to test the hypothesis that the variability in response to MTX is a function of inter-individual differences in folate homeostasis.

Methods: This is a single center prospective cohort study at a tertiary care children’s hospital evaluating newly treated JIA patients on standardized doses and routes of MTX (15mg/m2 PO) and folic acid (1mg/day).  After obtaining informed consent, samples are collected prior to, and after 3 and 6 months of MTX. Concentrations of tetrahydrofolate (THF), 5-methylTHF (5-MTHF), 5,10-methenylTHF (5,10-METHF), folic acid (FA),  and MTX polyglutamates (MTXGlun) are determined in plasma, whole blood and erythrocytes by UPLC-tandem mass spectrometry.  Clinical data are recorded from chart review and forms provided to the treating physician and patient/parent (CHAQ, MD VAS, PT VAS). Clinical outcomes at 3 months were measured via ACR pediatric 30, 50, 70 criteria and the JADAS71.  We report preliminary 3 month data on the first 20 patients recruited to the study.

Results:

The study consisted of 12 females and 8 males with JIA.  The mean (± SD) age at study entry was 135.2 (± 49.5) months.  After 3 months on standardized MTX therapy, paired t-test revealed an overall statistically significant decline in MD VAS (p < 0.0001), PT VAS (p < 0.001), active joint count (p = 0.002), JADAS71 (p < 0.001), and 5-MTHF concentrations (p= 0.004). There were no statistically significant differences in CHAQ, ESR, CRP, or 5,10-METHF from 0-3 months on therapy.  These results were confirmed with additional nonparametric testing.  At 3 months, 8 (40%) subjects failed to reach ACR Ped 30 (“non-responders”), while 10 (50%) subjects reached ACR Ped 30 or 50, and 2 (10%) reached ACR Ped 70 (“responders”).

The mean decline from baseline of 5-MTHF concentrations at 3 months was found to be significantly greater in boys (-420.8 nmol/L), compared to girls (-122.9 nmol/L) (p=0.03), and negatively correlated with age (ρ=-0.7, p=0.0006). A trend towards greater changes in 5-MTHF concentrations from baseline were observed in responders (-333.3 nmol/L) compared to non-responders (-105.1 nmol/L) (p=0.07). No statistically significant differences were seen in absolute 5-MTHF concentrations at 0 or 3 months and ACR outcomes, although responders had comparatively higher 5-MTHF concentrations (885.3 nmol/L vs. 666.2 nmol/L, p NS) at baseline.  Multivariate testing supported an association between change in 5-MTHF and response (p=0.05) controlling for gender and age.  Two patients had exceptionally high 5,10-METHF concentrations (>4x IQR).  Omitting the outliers revealed a pronounced change in 5-MTHF in responders (p=0.04).  No association between long chain MTXGlu and outcomes or change in folate concentrations has been observed to date.

Conclusion: These preliminary data suggest that an initial decline in 5-MTHF concentrations may be correlated to MTX response, and might provide clinicians with a more effective biomarker than intra-cellular concentrations of the drug itself in JIA.  Future work will investigate factors that contribute to 5-MTHF depletion.


Disclosure:

L. van Haandel,
None;

R. S. Funk,
None;

M. F. Ibarra,
None;

M. F. Hoeltzel,
None;

A. Lasky,
None;

D. Dai,
None;

R. Gaedigk,
None;

J. S. Leeder,
None;

M. L. Becker,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/degree-of-initial-intracellular-folate-depletion-may-predict-methotrexate-response-in-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences